PL1747023T3 - Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych - Google Patents

Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych

Info

Publication number: PL1747023T3
Authority: PL; Poland
Prior art keywords: target cell; methods; viral genome; compositions; hcv viral
Prior art date: 2004-05-04

Application number

PL05749437T

Other languages

English (en)

Other versions

PL1747023T5 (pl

Inventor

Peter Sarnow

Catherine L Jopling

Alissa M Lancaster

Original Assignee

Univ Leland Stanford Junior

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-04

Filing date

2005-05-03

Publication date

2011-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1747023(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-03 Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior

2011-08-31 Publication of PL1747023T3 publication Critical patent/PL1747023T3/pl

2017-05-31 Publication of PL1747023T5 publication Critical patent/PL1747023T5/pl

Links

230000003612 virological effect Effects 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
108091070501 miRNA Proteins 0.000 abstract 2
239000002679 microRNA Substances 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PL05749437T 2004-05-04 2005-05-03 Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych PL1747023T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US56835804P	2004-05-04	2004-05-04
EP05749437.9A EP1747023B2 (en)	2004-05-04	2005-05-03	Methods and compositions for reducing hcv viral genome amounts in a target cell
PCT/US2005/015264 WO2005107816A2 (en)	2004-05-04	2005-05-03	Methods and compositions for reducing viral genome amounts in a target cell

Publications (2)

Publication Number	Publication Date
PL1747023T3 true PL1747023T3 (pl)	2011-08-31
PL1747023T5 PL1747023T5 (pl)	2017-05-31

Family

ID=35320743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05749437T PL1747023T5 (pl)	2004-05-04	2005-05-03	Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych

Country Status (15)

Country	Link
US (6)	US7307067B2 (pl)
EP (3)	EP2500431A3 (pl)
JP (2)	JP4943322B2 (pl)
AT (1)	ATE494373T2 (pl)
AU (1)	AU2005240118C1 (pl)
CA (2)	CA2912903A1 (pl)
CY (1)	CY1111755T1 (pl)
DE (1)	DE602005025751D1 (pl)
DK (1)	DK1747023T4 (pl)
ES (1)	ES2361458T5 (pl)
IL (1)	IL178679B (pl)
PL (1)	PL1747023T5 (pl)
PT (1)	PT1747023E (pl)
SI (1)	SI1747023T1 (pl)
WO (1)	WO2005107816A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2530157B1 (en)	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of miRNAs
EP1793674B1 (en) *	2003-11-26	2018-05-30	University of Massachusetts	Sequence-specific inhibtion of small rna function
PT1747023E (pt) *	2004-05-04	2011-04-11	Univ Leland Stanford Junior	Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
EP2290073A3 (en)	2004-05-28	2011-08-31	Asuragen, Inc.	Methods and compositions involving microRNA
CA2857878A1 (en)	2004-11-12	2006-12-28	Asuragen, Inc.	Methods and compositions involving mirna and mirna inhibitor molecules
WO2006113431A2 (en) *	2005-04-13	2006-10-26	University Of Massachusetts	Dual functional oligonucleotides for use as anti-viral agents
US20070213292A1 (en)	2005-08-10	2007-09-13	The Rockefeller University	Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1919512B1 (en) *	2005-08-10	2014-11-12	Alnylam Pharmaceuticals Inc.	Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
US7516342B2 (en)	2005-12-30	2009-04-07	Intel Corporation	Method, apparatus and system to dynamically choose an optimum power state
DK2666859T3 (en)	2006-04-03	2019-04-08	Roche Innovation Ct Copenhagen As	PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2261333B1 (en) *	2006-04-03	2016-03-30	Roche Innovation Center Copenhagen A/S	Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
CA2663878A1 (en) *	2006-09-19	2008-03-27	Asuragen, Inc.	Mir-200 regulated genes and pathways as targets for therapeutic intervention
AU2008228243B2 (en)	2007-03-22	2014-05-15	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2149605T3 (da)	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
JP5149528B2 (ja) *	2007-03-30	2013-02-20	学校法人東京医科大学	Ｃ型肝炎ウイルスの複製を制御するマイクロｒｎａ
WO2009029681A2 (en) *	2007-08-27	2009-03-05	The Regents Of The University Of California	Micrornas for inhibiting viral replication
EP2198050A1 (en)	2007-09-14	2010-06-23	Asuragen, INC.	Micrornas differentially expressed in cervical cancer and uses thereof
ES2463665T3 (es)	2007-10-04	2014-05-28	Stella Aps	Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
WO2009070805A2 (en)	2007-12-01	2009-06-04	Asuragen, Inc.	Mir-124 regulated genes and pathways as targets for therapeutic intervention
EP2268811A1 (en)	2008-03-07	2011-01-05	Santaris Pharma A/S	Pharmaceutical compositions for treatment of microrna related diseases
US8258111B2 (en)	2008-05-08	2012-09-04	The Johns Hopkins University	Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8492357B2 (en)	2008-08-01	2013-07-23	Santaris Pharma A/S	Micro-RNA mediated modulation of colony stimulating factors
EP3067359A1 (en)	2008-09-23	2016-09-14	Scott G. Petersen	Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
EP2191834A1 (en) *	2008-11-26	2010-06-02	Centre National De La Recherche Scientifique (Cnrs)	Compositions and methods for treating retrovirus infections
JP5773535B2 (ja) *	2009-04-24	2015-09-02	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
EP2558578B1 (en)	2010-04-13	2015-10-28	Life Technologies Corporation	Compositions and methods for inhibition of nucleic acids function
DK2561078T3 (en)	2010-04-23	2019-01-14	Cold Spring Harbor Laboratory	NEW STRUCTURALLY DESIGNED SHRNAs
EP2663323B1 (en)	2011-01-14	2017-08-16	The General Hospital Corporation	Methods targeting mir-128 for regulating cholesterol/lipid metabolism
WO2013040251A2 (en)	2011-09-13	2013-03-21	Asurgen, Inc.	Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
CA2811203C (en)	2011-10-21	2015-05-05	Abbvie Inc.	Methods for treating hcv
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
EP2992095B1 (en)	2013-05-01	2019-01-09	Regulus Therapeutics Inc.	Microrna compounds and methods for modulating mir-122
AU2014300981B2 (en)	2013-06-27	2017-08-10	Ricc A/S	Antisense oligomers and conjugates targeting PCSK9
EP3198012B1 (en)	2014-09-26	2019-09-04	University of Massachusetts	Rna-modulating agents
EP3218485A1 (en)	2014-11-10	2017-09-20	Glaxosmithkline Intellectual Property (No. 2) Limited	Long acting pharmaceutical compositions for hepatitis c
SG11201703646SA (en)	2014-11-10	2017-06-29	Glaxosmithkline Intellectual Property (No 2) Ltd	Combination long acting compositions and methods for hepatitis c
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3790972A1 (en)	2018-05-08	2021-03-17	Regulus Therapeutics Inc.	Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN111904973B (zh) *	2020-07-27	2021-12-03	中国农业科学院兰州兽医研究所	ssc-miR-122在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
EP0737750B1 (en)	1989-03-21	2003-05-14	Vical, Inc.	Expression of exogenous polynucleotide sequences in a vertebrate
US5610050A (en) *	1990-04-20	1997-03-11	The General Hospital Corporation	Methods of preventing viral replication
JPH06311885A (ja) †	1992-08-25	1994-11-08	Mitsubishi Kasei Corp	Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
US6423489B1 (en) †	1992-09-10	2002-07-23	Isis Pharmaceuticals, Inc.	Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5985847A (en)	1993-08-26	1999-11-16	The Regents Of The University Of California	Devices for administration of naked polynucleotides which encode biologically active peptides
JPH10503364A (ja) †	1994-05-10	1998-03-31	ザジェネラルホスピタルコーポレーション	Ｃ型肝炎ウイルスのアンチセンス阻害
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
EP0877600B1 (en)	1996-08-09	2003-10-22	Alcon Manufacturing Ltd.	Preservative systems for pharmaceutical compositions containing cyclodextrins
US6824768B2 (en) *	1998-12-18	2004-11-30	Schering Corporation	Ribavirin-pegylated interferon alfa induction HCV combination therapy
EP1383782A1 (en) *	2001-03-26	2004-01-28	Sirna Therpeutics, Inc.	Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
FR2830254B1 (fr) *	2001-09-28	2004-09-17	Synkem	Nouvelles diphosphines, leurs complexes avec des metaux de transition et leur utilisation en synthese asymetrique
CA2462144C (en) *	2001-09-28	2016-09-20	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Micro-rna molecules
GB2397062B (en)	2002-02-20	2005-06-15	Sirna Therapeutics Inc	RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20040175732A1 (en) *	2002-11-15	2004-09-09	Rana Tariq M.	Identification of micrornas and their targets
CN1768139A (zh) *	2003-02-10	2006-05-03	独立行政法人产业技术总合研究所	通过dna干扰调控基因的表达
MXPA05008106A (es) *	2003-02-18	2005-09-21	Pfizer	Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
EP2530157B1 (en)	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of miRNAs
US20070270361A1 (en)	2003-08-04	2007-11-22	Shan Lu	Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
WO2005013905A2 (en)	2003-08-07	2005-02-17	Avi Biopharma, Inc.	SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
EP1793674B1 (en) *	2003-11-26	2018-05-30	University of Massachusetts	Sequence-specific inhibtion of small rna function
PT1747023E (pt) *	2004-05-04	2011-04-11	Univ Leland Stanford Junior	Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
US20070213292A1 (en)	2005-08-10	2007-09-13	The Rockefeller University	Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DK1931780T3 (en)	2005-08-29	2016-01-25	Regulus Therapeutics Inc	Antisense-forbindelser med forøget anti-microrna-aktivitet
DK2666859T3 (en)	2006-04-03	2019-04-08	Roche Innovation Ct Copenhagen As	PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
ES2463665T3 (es)	2007-10-04	2014-05-28	Stella Aps	Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
WO2011000092A1 (en)	2009-06-29	2011-01-06	Matthew Hunsberger	A disc brake for a tape measure

2005
- 2005-05-03 PT PT05749437T patent/PT1747023E/pt unknown
- 2005-05-03 EP EP12163232.7A patent/EP2500431A3/en not_active Withdrawn
- 2005-05-03 AT AT05749437T patent/ATE494373T2/de active
- 2005-05-03 US US11/122,328 patent/US7307067B2/en not_active Expired - Fee Related
- 2005-05-03 AU AU2005240118A patent/AU2005240118C1/en not_active Ceased
- 2005-05-03 EP EP10196635.6A patent/EP2338996A3/en not_active Withdrawn
- 2005-05-03 ES ES05749437.9T patent/ES2361458T5/es not_active Expired - Lifetime
- 2005-05-03 DK DK05749437.9T patent/DK1747023T4/en active
- 2005-05-03 PL PL05749437T patent/PL1747023T5/pl unknown
- 2005-05-03 CA CA2912903A patent/CA2912903A1/en not_active Abandoned
- 2005-05-03 SI SI200531259T patent/SI1747023T1/sl unknown
- 2005-05-03 EP EP05749437.9A patent/EP1747023B2/en not_active Expired - Lifetime
- 2005-05-03 WO PCT/US2005/015264 patent/WO2005107816A2/en not_active Ceased
- 2005-05-03 JP JP2007511489A patent/JP4943322B2/ja not_active Expired - Fee Related
- 2005-05-03 CA CA2564503A patent/CA2564503C/en not_active Expired - Fee Related
- 2005-05-03 DE DE602005025751T patent/DE602005025751D1/de not_active Expired - Lifetime
2006
- 2006-10-17 IL IL178679A patent/IL178679B/en not_active IP Right Cessation
2007
- 2007-12-10 US US11/953,705 patent/US7838504B2/en not_active Expired - Fee Related
2010
- 2010-11-19 US US12/950,672 patent/US8217020B2/en not_active Expired - Fee Related
2011
- 2011-04-04 CY CY20111100346T patent/CY1111755T1/el unknown
- 2011-12-26 JP JP2011282593A patent/JP5602123B2/ja not_active Expired - Fee Related
2012
- 2012-06-21 US US13/529,694 patent/US8759312B2/en not_active Expired - Fee Related
2014
- 2014-05-16 US US14/280,156 patent/US9416362B2/en not_active Expired - Fee Related
2016
- 2016-08-12 US US15/235,946 patent/US20160348116A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1747023B2 (en)	2016-03-09
AU2005240118A1 (en)	2005-11-17
AU2005240118C1 (en)	2014-02-13
CA2912903A1 (en)	2005-11-17
PL1747023T5 (pl)	2017-05-31
DE602005025751D1 (de)	2011-02-17
US7838504B2 (en)	2010-11-23
US8759312B2 (en)	2014-06-24
DK1747023T4 (en)	2016-05-02
DK1747023T3 (da)	2011-04-18
AU2005240118B2 (en)	2011-09-08
ES2361458T3 (es)	2011-06-17
JP4943322B2 (ja)	2012-05-30
EP2500431A3 (en)	2013-12-18
CA2564503C (en)	2015-12-29
US20150005362A1 (en)	2015-01-01
WO2005107816A2 (en)	2005-11-17
EP2338996A2 (en)	2011-06-29
EP2338996A3 (en)	2013-12-18
ATE494373T2 (de)	2011-01-15
EP1747023A2 (en)	2007-01-31
JP5602123B2 (ja)	2014-10-08
JP2012102116A (ja)	2012-05-31
US7307067B2 (en)	2007-12-11
US8217020B2 (en)	2012-07-10
PT1747023E (pt)	2011-04-11
IL178679B (en)	2019-01-31
US20080234220A1 (en)	2008-09-25
SI1747023T1 (sl)	2011-06-30
ES2361458T5 (es)	2016-04-20
EP1747023A4 (en)	2010-03-03
EP1747023B1 (en)	2011-01-05
CY1111755T1 (el)	2015-10-07
CA2564503A1 (en)	2005-11-17
JP2007536242A (ja)	2007-12-13
US20110124707A1 (en)	2011-05-26
US9416362B2 (en)	2016-08-16
EP2500431A2 (en)	2012-09-19
US20120329856A1 (en)	2012-12-27
IL178679A0 (en)	2007-02-11
WO2005107816A3 (en)	2006-02-23
US20050288245A1 (en)	2005-12-29
US20160348116A1 (en)	2016-12-01

Publication	Publication Date	Title
IL178679A0 (en)	2007-02-11	Methods and compositions for reducing viral genome amounts in a target cell
WO2006130627A3 (en)	2008-02-07	Methods for treating hepatitis c
WO2007131072A3 (en)	2008-07-03	Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2004014312A3 (en)	2005-02-17	Small-mer compositions and methods of use
WO2009091388A3 (en)	2009-10-22	Triazines and related compounds having antiviral activity, compositions and methods thereof
WO2008021936A3 (en)	2008-04-17	Hepatitis c virus inhibitors
WO2005123087A3 (en)	2006-07-13	C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2008106058A3 (en)	2009-03-26	Inhibitors of serine proteases
WO2011123645A3 (en)	2011-12-29	Nucleoside phosphoramidates
WO2005087725A3 (en)	2005-10-27	Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A3 (en)	2005-11-10	Compounds as inhibitors of hepatitis c virus ns3 serine protease
ZA200900935B (en)	2010-03-31	Hepatitis C virus inhibitors
WO2010034670A3 (en)	2010-11-18	Host cell kinases as targets for antiviral therapies against hcv infection
WO2005116250A3 (en)	2006-07-06	Viral and viral associated mirnas and uses thereof
MX2010001733A (es)	2010-07-06	Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
WO2005116002A3 (en)	2006-07-06	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005087731A8 (en)	2006-06-22	Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007111866A3 (en)	2008-06-19	Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2004009020A3 (en)	2005-02-24	Pyrrolopyrimidine thionucleoside analogs as antivirals
WO2010101649A3 (en)	2011-01-13	Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
MX2010009563A (es)	2010-09-24	Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
MA33209B1 (fr)	2012-04-02	Inhibiteurs de la replication du virus de l'hepatite c
WO2006078284A3 (en)	2006-09-28	Methods and compositions related to antiviral therapy using algae and cyanobacteria
WO2009141731A3 (en)	2010-03-11	The large form of human 2', 5'-oligoadenylate synthetase oas3 for preventing or treating infection with positive-sense single-stranded rna viruses
WO2006085979A3 (en)	2009-04-09	Soluble forms of hendra and nipah virus g glycoprotein